medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2018, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2018; 63 (4)

Bone morphogenetic proteins. Basic science and surgical orthopedic applications

Álvarez MR

Language: Spanish
References: 85
Page: 273-282
PDF size: 275.94 Kb.


ABSTRACT

Bone morphogenetic proteins are a group of cytokines with pleiotropic effects that belong to the transforming growth factor-beta superfamily. Their implications in orthopedic surgery became important because of their osteoinductive properties noted first by Marshall Urist, and later, with the development of cloned proteins and their potential clinical applications in bone healing. This document will review in brief the basic concepts about their physiologic synthesis, molecular structure, classification, biochemical properties and effects on the musculoskeletal system, but also, the technology involved in their industrial production as health goods applied as biologic reconstruction devices in orthopedic surgery.


REFERENCES

  1. Urist MR, Silverman BF, Büring K, Dubuc FL, Rosenberg JM. The bone induction principle. Clin Orthop Relat Res. 1967; 53: 243-283.

  2. Urist MR. Bone: formation by autoinduction. Science. 1965; 150 (3698): 893-899.

  3. Peterson B, Whang PG, Iglesias R, Wang JC, Lieberman JR. Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model. J Bone Joint Surg Am. 2004; 86-A (10): 2243-2250.

  4. Edwards JT, Diegmann MH, Scarborough NL. Osteoinduction of human demineralized bone: characterization in a rat model. Clin Orthop Relat Res. 1998; (357): 219-228.

  5. Katz J, Diegl EC, Nataraj C. Time course of DBM-induced intermuscular endochondral ossification. Orthopedic Research Society Meeting (2006) abs.912.

  6. Bostrom MP, Seigerman DA. The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. HSS J. 2005; 1 (1): 9-18.

  7. Kanakaris NK, Giannoudis PV. Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv. 2008; 17 (3): 133-146.

  8. Gruskin E, Doll BA, Futrell FW, Schmitz JP, Hollinger JO. Demineralized bone matrix in bone repair: history and use. Adv Drug Deliv Rev. 2012; 64 (12): 1063-1077.

  9. Weiss A, Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol. 2013; 2 (1): 47-63.

  10. Santibańez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011; 121 (6): 233-251.

  11. Urist MR. Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res. 1997; 12 (3): 343-346.

  12. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science. 1996; 271 (5247): 360-362.

  13. Urist MR, Hay PH, Dubuc F, Buring K. Osteogenetic competence. Clin Orthop Relat Res. 1969; 64: 194-220.

  14. Urist MR, Iwata H, Ceccotti PL, Dorfman RL, Boyd SD, McDowell RM et al. Bone morphogenesis in implants of insoluble bone gelatin. Proc Natl Acad Sci U S A. 1973; 70 (12): 3511-3515.

  15. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res. 1971; 50 (6): 1392-1406.

  16. Reddi AH, Huggins C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci U S A. 1972; 69 (6): 1601-1605.

  17. Reddi AH, Anderson WA. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J Cell Biol. 1976; 69 (3): 557-572.

  18. Reddi AH. Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials. Tissue Eng. 2000; 6 (4): 351-359.

  19. Albrektsson T, Johansson C. Osteoinduction, osteoconduction and osseointegration. Eur Spine J. 2001; 10 Suppl 2: S96-S101.

  20. Sampath TK, Muthukumaran N, Reddi AH. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci U S A. 1987; 84 (20): 7109-7113.

  21. Jennings JC, Mohan S, Baylink DJ. Purification of bovine skeletal growth factor. Methods Enzymol. 1987; 146: 281-294.

  22. Urist MR, Chang JJ, Lietze A, Huo YK, Brownell AG, DeLange RJ. Preparation and bioassay of bone morphogenetic protein and polypeptide fragments. Methods Enzymol. 1987; 146: 294-312.

  23. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242 (4885): 1528-1534.

  24. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A. 1988; 85 (24): 9484-9488.

  25. Wang EA, Rosen V, D’Alessandro JS, Bauduy M, Cordes P, Harada T et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A. 1990; 87 (6): 2220-2224.

  26. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 1997; 8 (1): 11-20.

  27. Wozney JM. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976). 2002; 27 (16 Suppl 1): S2-S8.

  28. Sartori R, Sandri M. Bone and morphogenetic protein signalling and muscle mass. Curr Opin Clin Nutr Metab Care. 2015; 18 (3): 215-220.

  29. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006; 45 (4): 375-388.

  30. Alarmo EL, Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer. 2010; 17 (2): R123-R139.

  31. Hardwick JC, Kodach LL, Offerhaus GJ, van den Brink GR. Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer. 2008; 8 (10): 806-812.

  32. Sipe JB, Zhang J, Waits C, Skikne B, Garimella R, Anderson HC. Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. Bone. 2004; 35 (6): 1316-1322.

  33. Garimella R, Tague SE, Zhang J, Belibi F, Nahar N, Sun BH et al. Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J Histochem Cytochem. 2008; 56 (6): 569-577.

  34. Tsumaki N, Nakase T, Miyaji T, Kakiuchi M, Kimura T, Ochi T et al. Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. J Bone Miner Res. 2002; 17 (5): 898-906.

  35. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am. 2002; 84-A (6): 1032-1044.

  36. Sánchez-Duffhues G, Hiepen C, Knaus P, Ten Dijke P. Bone morphogenetic protein signaling in bone homeostasis. Bone. 2015; 80: 43-59.

  37. Kopf J, Paarmann P, Hiepen C, Horbelt D, Knaus P. BMP growth factor signaling in a biomechanical context. Biofactors. 2014; 40 (2): 171-187.

  38. Nomura S, Takano-Yamamoto T. Molecular events caused by mechanical stress in bone. Matrix Biol. 2000; 19 (2): 91-96.

  39. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009; 20 (5-6): 343-355.

  40. Lowery JW, Amich JM, Andonian A, Rosen V. N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding. Cell Mol Life Sci. 2014; 71 (16): 3165-3172.

  41. Constam DB, Robertson EJ. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol. 1999; 144 (1): 139-149.

  42. Nelsen SM, Christian JL. Site-specific cleavage of BMP4 by furin, PC6, and PC7. J Biol Chem. 2009; 284 (40): 27157-27166.

  43. Harrison CA, Al-Musawi SL, Walton KL. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands. Growth Factors. 2011; 29 (5): 174-186.

  44. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors. 1996; 13 (3-4): 291-300.

  45. Valera E, Isaacs MJ, Kawakami Y, Izpisúa Belmonte JC, Choe S. BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells. PLoS One. 2010; 5 (6): e11167.

  46. Yang J, Shi P, Tu M, Wang Y, Liu M, Fan F et al. Bone morphogenetic proteins: relations between molecular structure and their osteogenic activity. Food Sci Hum Well 2014; 3 (3-4): 127-135.

  47. Scheufler C, Sebald W, Hülsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol. 1999; 287 (1): 103-115.

  48. Rahman MS, Akhtar N, Jamil HM, Banik RS, Asaduzzaman SM. TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation. Bone Res. 2015; 3: 15005.

  49. Board TN, Rooney P, Kay PR. Strain imparted during impaction grafting may contribute to bony incorporation: an in vitro study of the release of bmp-7 from allograft. J Bone Joint Surg Br. 2008; 90 (6): 821-824.

  50. Guo J, Wu G. The signaling and functions of heterodimeric bone morphogenetic proteins. Cytokine Growth Factor Rev. 2012; 23 (1-2): 61-67.

  51. Salazar VS, Gamer LW, Rosen V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol. 2016; 12 (4): 203-221.

  52. Heinecke K, Seher A, Schmitz W, Mueller TD, Sebald W, Nickel J. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biol. 2009; 7: 59.

  53. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells. 2002; 7 (12): 1191-1204.

  54. Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell. 2008; 29 (2): 157-168.

  55. Radaev S, Zou Z, Huang T, Lafer EM, Hinck AP, Sun PD. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem. 2010; 285 (19): 14806-14814.

  56. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113 (6): 685-700.

  57. Blair CR, Stone JB, Wells RG. The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase. Biochim Biophys Acta. 2011; 1813 (2): 332-339.

  58. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science. 2002; 296 (5573): 1646-1647.

  59. Miyazono K. TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 2000; 11 (1-2): 15-22.

  60. Mollenhauer JA, Jandt KD, Hortschanky P. Ceramics in Orthopedics. Session 8.3. Application of bone morphogenetic proteins on solid implants. En: Belazzo F, Falez F, Dietrich M. 11th BIOLOX Symposium Rome, June 30-July 1, 2006 Proceedings. Bioceramics and Alternative Bearings in Joint Arthroplaty. Springer; 2006. pp. 277-282.

  61. Israel DI, Nove J, Kerns KM, Moutsatsos IK, Kaufman RJ. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors. 1992; 7 (2): 139-150.

  62. Kaufman RJ. Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol. 1990; 185: 537-566.

  63. Kaufman RJ, Wasley LC, Spiliotes AJ, Gossels SD, Latt SA, Larsen GR et al. Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol Cell Biol. 1985; 5 (7): 1750-1759.

  64. Tanaka H, Tapscott SJ, Trask BJ, Yao MC. Short inverted repeats initiate gene amplification through the formation of a large DNA palindrome in mammalian cells. Proc Natl Acad Sci U S A. 2002; 99 (13): 8772-8777.

  65. Damien CJ, Grob D, Boden SD, Benedict JJ. Purified bovine BMP extract and collagen for spine arthrodesis: preclinical safety and efficacy. Spine (Phila Pa 1976). 2002; 27 (16 Suppl 1): S50-S58.

  66. Friess W. Collagen—biomaterial for drug delivery. Eur J Pharm Biopharm. 1998; 45 (2): 113-136.

  67. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002; 84-A (12): 2123-2134.

  68. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res. 2002; (395): 110-120.

  69. Arrabal PM, Visser R, Santos-Ruiz L, Becerra J, Cifuentes M. Osteogenic molecules for clinical applications: improving the BMP-collagen system. Biol Res. 2013; 46 (4): 421-429.

  70. Uludag H, Gao T, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am. 2001; 83-A Suppl 1 (Pt 2): S128-S135.

  71. Peel SA, Hu ZM, Clokie CM. In search of the ideal bone morphogenetic protein delivery system: in vitro studies on demineralized bone matrix, purified, and recombinant bone morphogenetic protein. J Craniofac Surg. 2003; 14 (3): 284-291.

  72. Brondyk WH. Selecting an appropriate method for expressing a recombinant protein. Methods Enzymol. 2009; 463: 131-147.

  73. Bessa PC, Cerqueira MT, Rada T, Gomes ME, Neves NM, Nobre A et al. Expression, purification and osteogenic bioactivity of recombinant human BMP-4, -9, -10, -11 and -14. Protein Expr Purif. 2009; 63 (2): 89-94.

  74. Sharapova NE, Kotnova AP, Galushkina ZM, Lavrova NV, Poletaeva NN, Tukhvatulin AE et al. Production of the recombinant human bone morphogenetic protein-2 in Escherichia coli and testing of its biological activity in vitro and in vivo. Mol Biol (Mosk). 2010; 44 (6): 1036-1044.

  75. Maruoka Y, Oida S, Iimura T, Takeda K, Asahina I, Enomoto S et al. Production of functional human bone morphogenetic protein-2 using a baculovirus/Sf-9 insect cell system. Biochem Mol Biol Int. 1995; 35 (5): 957-963.

  76. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A et al. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am. 2006; 88 (6): 1258-1265.

  77. Mont MA, Etienne G, Ragland PS. Outcome of nonvascularized bone grafting for osteonecrosis of the femoral head. Clin Orthop Relat Res. 2003; (417): 84-92.

  78. Seyler TM, Marker DR, Ulrich SD, Fatscher T, Mont MA. Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis. Clin Orthop Relat Res. 2008; 466 (5): 1125-1132.

  79. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014; 32 (10): 992-1000.

  80. Hamilton DK, Smith JS, Reames DL, Williams BJ, Shaffrey CI. Use of recombinant human bone morphogenetic protein-2 as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: An analysis of safety, efficacy, and dosing. J Craniovertebr Junction Spine. 2010; 1 (2): 107-112.

  81. Wiwanitkit V. The concern on clinical use of recombinant human bone morphogenetic protein-2. J Craniovertebr Junction Spine. 2011; 2 (2): 102-103.

  82. Taghavi CE, Lee KB, He W, Keorochana G, Murray SS, Brochmann EJ et al. Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing. Spine (Phila Pa 1976). 2010; 35 (23): 2049-2056.

  83. Yeh TT, Wu SS, Lee CH, Wen ZH, Lee HS, Yang Z et al. The short-term therapeutic effect of recombinant human bone morphogenetic protein-2 on collagenase-induced lumbar facet joint osteoarthritis in rats. Osteoarthritis Cartilage. 2007; 15 (12): 1357-1366.

  84. Carragee EJ, Chu G, Rohatgi R, Hurwitz EL, Weiner BK, Yoon ST et al. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am. 2013; 95 (17): 1537-1545.

  85. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013; 158 (12): 890-902.




2020     |     www.medigraphic.com